Doximity's stock price jumped as much as 105% in early trading on August 7, 2026, after the company raised its profit outlook for the year. Two things drove the surge: a massive increase in doctors using its AI note-taking tool and a first-place finish in a safety study run by researchers at Stanford and Harvard (Tech Times).

The news came out alongside Doximity's quarterly earnings report, which was scheduled for August 6, 2026 (Doximity Investor Relations). That same day, the company announced that its AI tool for doctors ranked higher than competing products from OpenEvidence and other major AI companies in an independent safety study (Doximity Press).

An "AI scribe" is a tool that listens to a conversation between a doctor and patient and automatically writes up the medical notes. Usage of Doximity's AI scribe grew ten times over, which suggests doctors are actually using it in their daily work rather than just trying it out. That matters because Doximity makes money by keeping doctors active on its platform, which attracts drug companies that want to advertise to those doctors.

The safety study result gives Doximity a second boost. When it comes to medical AI, trust is everything — if doctors don't feel a tool is safe, they won't use it. Beating well-known competitors in a study run by two top universities gives Doximity credibility that most companies in this field can't claim, since many simply run their own tests and report the results.

The broader context here is that investors have long questioned whether AI tools for healthcare can turn into real, lasting revenue. Doximity's announcement answers that question on two fronts at once: doctors are genuinely using the product, and independent researchers confirmed it's safe. The stock's sharp jump suggests investors found both points convincing.

A 105% jump in early trading means investors are rapidly rethinking what the company is worth. The raised profit outlook ties the surge to expected real revenue rather than hype. The safety study win suggests doctors may stick with Doximity's tool rather than switch to a competitor, which could make the company's advantage grow over time.

Whether the early surge holds once regular trading starts will depend on the details of the earnings report, the new profit outlook, and whether company leaders say the AI scribe growth can continue. Big early-morning jumps like this often see some investors sell to lock in gains once the market opens, so the final closing price will offer the first real signal of how confident investors actually are.

The competitive angle is worth keeping an eye on. The companies Doximity beat in the safety study are serious players. If the study's methods hold up to outside review, Doximity's win could push competitors to do better on safety validation. But one study, even from top universities, is still just one study. More research from other institutions will be needed to know whether Doximity's edge is here to stay.